Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemically synthesized, non-capped and non-polyadenylated peptide-coding RNA efficiently induces antigen-specific CD8<sup>+</sup> T cells.

Nature biomedical engineering·2026
Same author

Validation of an improved insect bite hypersensitivity severity score for allergic equine insect bite hypersensitivity in horses.

Journal of veterinary internal medicine·2026
Same author

Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice.

Frontiers in allergy·2026
Same author

Carprofen and buprenorphine delivery using micropipette-guided drug administration (MDA) in mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings.

BMJ open·2026
Same author

Moving beyond oral gavage: micropipette-guided drug administration (MDA) as a 3R refinement for voluntary oral drug delivery in rodents.

Lab animal·2026

Related Experiment Video

Updated: May 31, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Intralymphatic immunotherapy: from the rationale to human applications.

Gabriela Senti1, Pål Johansen, Thomas M Kündig

  • 1Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. gabriela.senti@usz.ch

Current Topics in Microbiology and Immunology
|July 5, 2011
PubMed
Summary

Intralymphatic allergen administration significantly enhances allergen specific immunotherapy (SIT), reducing required injections and allergen dose. This novel approach makes SIT safer, faster, and more convenient for patients with IgE-mediated allergies.

More Related Videos

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Related Experiment Videos

Last Updated: May 31, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Area of Science:

  • Immunology
  • Allergy Treatment
  • Vaccine Development

Background:

  • Allergen specific immunotherapy (SIT) is a causative treatment for IgE-mediated allergies with long-term effects.
  • Traditional SIT involves years of subcutaneous allergen injections.
  • Sublingual immunotherapy offers an alternative but has not shortened treatment duration.

Purpose of the Study:

  • To review the direct administration of allergens into lymph nodes to enhance SIT.
  • To evaluate the efficacy of intralymphatic allergen administration in improving immunotherapy outcomes.
  • To assess the safety and patient convenience of intralymphatic immunotherapy.

Main Methods:

  • Review of studies on direct antigen administration into lymph nodes.
  • Focus on intralymphatic allergen administration in mouse models and clinical trials.
  • Assessment of immune responses, allergen dose, injection frequency, safety, and patient experience.

Main Results:

  • Intralymphatic allergen administration significantly enhances immune responses compared to traditional methods.
  • Treatment requires only three injections, with a 10-100 fold reduction in allergen dose.
  • Intralymphatic injections are easy, virtually painless, and safe in both animal models and humans.

Conclusions:

  • Intralymphatic immunotherapy markedly enhances protective immune responses.
  • This method reduces the number and dose of allergen injections, making SIT safer and faster.
  • Enhanced patient convenience and compliance are key benefits of intralymphatic immunotherapy.